Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maartje J Hooning

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
Cancer Causes & Control : CCC|March 5, 2020
The impact of lifestyle and reproductive factors on the risk of a second new primary cancer in the contralateral breast: a systematic review and meta-analysisDelal Akdeniz, M Maria Klaver, Chloé Z A Smith, et al.
Breast Cancer Research and Treatment|October 16, 2015
Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger ageJan Drooger, Delal Akdeniz, Jean-Philippe Pignol, et al.
Breast (Edinburgh, Scotland)|June 5, 2020
The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancerMark van Barele, Bernadette A M Heemskerk-Gerritsen, Helena C van Doorn, et al.
Breast (Edinburgh, Scotland)|September 20, 2020
Corrigendum to "The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer" [Breast 52 (2020) 102-109]Mark van Barele, Bernadette A M Heemskerk-Gerritsen, Helena C van Doorn, et al.
Cancer Treatment Reviews|December 24, 2014
Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literatureJan C Drooger, Maartje J Hooning, Caroline M Seynaeve, et al.
Cancer Cytopathology|May 31, 2013
Breast fine-needle aspiration cytology performance in the high-risk screening population: a study of BRCA1/BRCA2 mutation carriersRadka D Georgieva, Inge M Obdeijn, Agnes Jager, et al.
Acta Oncologica (Stockholm, Sweden)|July 1, 2024
The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancerMarie-Christina Jahreiß, Luca Incrocci, Katja K H Aben, et al.
JACC. Cardiooncology|April 17, 2025
Reply: Reassessing CAC Risk Post-RRSO: The Overlooked Role of Hormone TherapyMaarten J Beekman, Lara Terra, Bernadette A M Heemskerk-Gerritsen, et al.
Cancers|June 2, 2021
Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?Mark van Barele, Bernadette A M Heemskerk-Gerritsen, Yvonne V Louwers, et al.
Breast Cancer Research and Treatment|February 26, 2014
Should we screen BRCA1 mutation carriers only with MRI? A multicenter studyInge-Marie Obdeijn, Gonneke A O Winter-Warnars, Ritse M Mann, et al.
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
Cancer Causes & Control : CCC|March 5, 2020
The impact of lifestyle and reproductive factors on the risk of a second new primary cancer in the contralateral breast: a systematic review and meta-analysisDelal Akdeniz, M Maria Klaver, Chloé Z A Smith, et al.
Breast Cancer Research and Treatment|October 16, 2015
Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger ageJan Drooger, Delal Akdeniz, Jean-Philippe Pignol, et al.
Breast (Edinburgh, Scotland)|June 5, 2020
The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancerMark van Barele, Bernadette A M Heemskerk-Gerritsen, Helena C van Doorn, et al.
Breast (Edinburgh, Scotland)|September 20, 2020
Corrigendum to "The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer" [Breast 52 (2020) 102-109]Mark van Barele, Bernadette A M Heemskerk-Gerritsen, Helena C van Doorn, et al.
Cancer Treatment Reviews|December 24, 2014
Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literatureJan C Drooger, Maartje J Hooning, Caroline M Seynaeve, et al.
Cancer Cytopathology|May 31, 2013
Breast fine-needle aspiration cytology performance in the high-risk screening population: a study of BRCA1/BRCA2 mutation carriersRadka D Georgieva, Inge M Obdeijn, Agnes Jager, et al.
Acta Oncologica (Stockholm, Sweden)|July 1, 2024
The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancerMarie-Christina Jahreiß, Luca Incrocci, Katja K H Aben, et al.
JACC. Cardiooncology|April 17, 2025
Reply: Reassessing CAC Risk Post-RRSO: The Overlooked Role of Hormone TherapyMaarten J Beekman, Lara Terra, Bernadette A M Heemskerk-Gerritsen, et al.
Cancers|June 2, 2021
Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?Mark van Barele, Bernadette A M Heemskerk-Gerritsen, Yvonne V Louwers, et al.
Breast Cancer Research and Treatment|February 26, 2014
Should we screen BRCA1 mutation carriers only with MRI? A multicenter studyInge-Marie Obdeijn, Gonneke A O Winter-Warnars, Ritse M Mann, et al.
Pageof 20